WHO WE ARE
Pixelgen was founded in Stockholm, Sweden in 2020 to deliver the first DNA-based visualization technology for cell-surface proteomics.
We are:
WHAT WE DO
Pixelgen Technologies AB is on a mission to deliver biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies that decipher the protein interactomics of single cells in unprecedented ways. The company’s patented Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at ultra-high capacity and underpins the Pixelgen Proxiome Kit for precision medicine. A foundational technology, the Proximity Network Assay will power a portfolio of products for translational research to accelerate advances in immunology, hematology, and cell therapy. Pixelgen was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs and is venture-backed.
WE ARE JUST BEGINNING!
Imaging without light will enable us to achieve a level of throughput and multiplexing never before possible on the proteome. We believe this will lead to unexpected discoveries that will spark breakthroughs in diagnostics and therapeutics not just for cancer, but for autoimmune disease, infectious diseases, and much more.
Investors & Collaborators
Investor
Investor
Fibonacci Growth Capital
Investor
Collaborator
Collaborator
Collaborator
Advanced development activities supported by a contract with Wellcome Leap
Collaborator